C irrhosis results from any chronic liver disease and has 2 distinct stages: compensated and decompensated. The median survival in compensated cirrhosis is longer than 12 years, although it is fewer than 2 years once decompensation occurs, that is, when complications of cirrhosis (ascites, variceal hemorrhage, and/or encephalopathy) become clinically apparent. 1 The main predictors of decompensation are the presence of clinically significant portal hypertension (determined by portal pressure measurement) and a low serum albumin level (an indicator of liver dysfunction). 2, 3 A decrease in portal pressure of only 10% has been shown to decrease the development of varices significantly, 4 and reduce the incidence of first variceal hemorrhage, ascites, and death in patients with compensated cirrhosis. 5, 6 Most drugs currently used to decrease portal pressure do so through splanchnic vasoconstriction, thereby reducing portal blood inflow. However, an important component of portal hypertension is increased intrahepatic vascular resistance partially resulting from sinusoidal endothelial dysfunction with decreased nitric oxide. Statins increase nitric oxide availability at the intrahepatic level 7 and decrease portal pressure both in experimental animals 8 and in patients with cirrhosis. 9 Their beneficial effect may go beyond reducing portal pressure by increasing flow into the liver, thereby potentially improving liver function. 9 Although statins also can be hepatotoxic, a recent small retrospective study suggested that statins are safe in cirrhosis and their use was a negative predictor of death. 10 The objective of this study was to assess the association between statin use, decompensation, and death in a large cohort of patients with compensated cirrhosis. We hypothesized that statins would be associated with a lower risk of decompensation and death. Patients with more severe liver disease are less likely to be prescribed a statin but more likely to decompensate and die. Patients with more severe cardiovascular risks are more likely to receive a statin but may be at higher risk of death. To account for this confounding by indication we used propensity score matching. This technique provides an analysis that emulates a randomized trial.
Materials and Methods

Study Design and Data Source
This was a retrospective cohort study, approved by the Institutional Review Board of the Veterans Affairs (VA) Connecticut Health Care System. Data were obtained from the US Departments of VA Hepatitis C Virus (HCV) Clinical Case Registry (CCR); a database of HCV-infected Veterans receiving care in any VA facility nationwide. Subjects were included in the CCR if they had a positive HCV antibody or an International Classification of Diseases, 9th revision (ICD-9) code for hepatitis C; 80% of patients had a positive HCV RNA, a confirmatory test was not available in the remaining 20%. Data elements in the CCR include demographics, inpatient and outpatient visits (including ICD-9 diagnosis and procedure codes, and Current Procedural Terminology codes), laboratory results, and pharmacy data. Mortality was determined from the VA vital status file, which is compiled from combined sources including inpatient mortality, social security data, and national death benefit data, a method shown to provide excellent mortality ascertainment. 11 Details on the creation and contents of CCR data have been published elsewhere. 12 The data set used in the current study consisted of HCV patients in CCR receiving care between January 1, 1996, and December 31, 2009.
Study Patients
Included patients had cirrhosis, defined by the presence of 1 inpatient or 2 outpatient codes (ICD-9 codes 571.2, 571.5, and 571.6, as previously validated), 13 and who attended primary care/internal medicine, cardiology, endocrinology, gastroenterology, geriatrics, hepatology, infectious diseases, or women's health clinics. These clinics were chosen because they were the source of 85% of statin use and we wanted to ensure that users and nonusers came from the same source population and had an equal opportunity to receive a statin prescription. Patients with human immunodeficiency virus (ICD-9 codes 042, 044, and V08) or hepatitis B infection (positive surface antigen or positive hepatitis B virus DNA) were excluded.
The index date was defined as the date of first statin fill for statin users and a randomly chosen clinic visit date for statin nonusers (Supplementary Figure 1) between 2000 and 2009 (statin use was scarce before 2000). The baseline period was defined as 365 days before the index date. Baseline laboratory results used for the study were from this period and were the closest available to the index date. Statin users had to be newly initiating and were required to have at least 2 fills of any statin (simvastatin, lovastatin, rosuvastatin, atorvastatin, pravastatin, and fluvastatin). To ensure that patients received medications from the VA (and minimize the possibility of receiving a statin prescription from outside the VA) all patients had to have filled at least one VA prescription for any drug in the year before the index date ( Figure 1 and Supplementary Figure 1) . To ensure that statin users were new initiators, the index date had to be at least 180 days after the first VA nonstatin prescription of any kind. Patients were excluded if they had decompensation (as defined later) or hepatocellular carcinoma (ICD-9 code 155.0) before or within 180 days after the index date, no laboratory results, or no follow-up evaluation. Patients also were excluded if they died within 180 days after the index date ( Figure 1 and Supplementary Figure 1) . Statin users were excluded if they had only 1 statin prescription fill, or more than 365 days between the first and second fill. 
Study Outcomes
The primary outcomes were cirrhosis decompensation and death. Decompensation was defined by the presence of 1 inpatient or 2 outpatient ICD-9 codes for the following: (1) esophageal varices with bleeding (ICD-9 code 456.0), (2) esophageal varices in diseases classified elsewhere, with bleeding (ICD-9 code 456.20), (3) ascites (ICD 9 code 789.5), or (4) spontaneous bacterial peritonitis (ICD-9 code 567.23). This definition was modified from the original 14 by excluding the code for esophageal varices without bleeding (ICD-9 codes 456.1 and 456.21) and portal hypertension (572.3) because these are not decompensating events. 1 Outcomes analysis was restricted to patients with index dates before December 31, 2008 , to allow all patients the opportunity for at least 1 year of follow-up evaluation. Follow-up evaluation began 180 days after the index date (Supplementary Figure 1) to avoid immortal time bias. 15 That is, because statin users were guaranteed to be alive long enough to have a second fill, a similar allowance had to be made for nonusers. Most statin users had the second fill by 180 days. Follow-up evaluation for decompensation ended at the earliest of date of diagnosed decompensation liver transplant, death, or last visit recorded at the VA as of December 31, 2009 . Follow-up evaluation for death was similar but patients were not censored at decompensation or transplant.
Data Collection
Data collected included age, sex, race, body mass index (BMI), geographic site and its statin prescribing pattern, comorbid conditions, and laboratory data, as well as any prescription of antiviral therapy with pegylated interferon plus ribavirin during the study period. Comorbid conditions were defined as those recorded any time before the index date (Supplementary Figure 1) . Hypertension, peripheral artery disease, chronic kidney disease, coronary artery disease, cerebrovascular disease, smoking, diabetes, alcohol dependence, and drug abuse were determined based on the occurrence of at least 1 inpatient or 2 outpatient ICD-9 codes for the respective diagnoses. Baseline laboratory data on total cholesterol, lowdensity lipoprotein (LDL), high-density lipoprotein, triglycerides, albumin, total bilirubin, aspartate aminotransferase and alanine aminotransferase, international normalized ratio, platelet count, and hemoglobin were collected before and closest to the index date and within 365 days of the same. The number of lipid and nonlipid laboratory tests performed in the year before the index date also was obtained. The FIB-4 index was calculated at baseline as follows: (age in years Â aspartate aminotransferase level in U/L)/(platelet count Â 10 9 /L) Â (ALT level in U/L). 16 Prior studies have shown that it is useful in ruling in cirrhosis in patients with chronic liver disease, 17 and in compensated cirrhosis it can identify patients with clinically significant portal hypertension with reasonable accuracy (unpublished observations). Liver transplantation was identified using ICD-9 procedure codes and diagnosis codes. Adherence to therapy was assessed by an extensively studied method, the proportion of days covered, which is calculated as the cumulative number of days during which the medication was available divided by the number of days of follow-up evaluation.
18,19
Statistical Analysis Development of propensity score. To minimize confounding by indication, the study used a propensity scorematched cohort design. 20 Propensity scores were developed using covariates associated with statin use, both wellestablished predictors and also those specific to the patient population. The final multivariable logistic regression model included 33 variables and 3 interaction terms. We included age, body mass index, year of index visit, frequently occurring diagnoses in statin users (eg, coronary artery disease, cerebrovascular disease, smoking, and diabetes), laboratory values predictive of statin use (eg, LDL and total cholesterol), health care utilization variables (eg, number of laboratory tests and specialty clinic visited), and negative correlates of statin use (laboratory values indicating severity of liver disease; eg, albumin, total bilirubin, international normalized ratio, platelet count, and FIB-4 index). In addition, prescribing patterns were developed by determining the proportion of patients in the visit pool who initiated statin use at each site by years (1997-2001, 2002-2003, and 2004-2009 ). Sites below the 25th percentile were deemed as low statin-prescribing sites, sites above the 75th percentile were deemed high statin-prescribing sites; all other sites were classified as medium. This attribute was assigned to each record and used in the propensity score model. Adding prescribing patterns by geographic site and year, and interactions with diabetes and high-density lipoprotein by year, improved model fit and discrimination. The c-statistic for the propensity score model was 0.92, which indicates an excellent discrimination between statin users and nonusers. 21 
Matching
Statin users were matched by propensity scores to nonusers with a greedy matching algorithm. 22 First, all possible 5 decimal place matches were made, then 4 decimal places, and so on, down to 1 decimal place. Next, the 5 best matches for each user were selected randomly with each nonuser only selected once. The weighted average of each set of nonusers was used to represent 1 nonuser. Statin users who could not be matched were excluded from the matched cohort analysis. Subjects were assigned their original exposure status until the end of the follow-up evaluation regardless of actual statin use during the follow-up evaluation to emulate an intention-totreat analysis of a randomized trial.
Outcome Analysis
We performed parallel analyses in an unmatched sample of all eligible statin users compared with a sample of all eligible unique nonusers in whom the index date was selected randomly, and the propensity score-matched sample of users and nonusers. Kaplan-Meier curves were generated to compare primary outcomes in statin users and nonusers. The association between statin use and risk of mortality and decompensation was estimated using the Cox proportional hazards model with adjustment for age, FIB-4 index (as a surrogate of clinically significant portal hypertension), serum albumin, model for endstage liver disease (MELD) score, and Child-Turcotte-Pugh (CTP) score; parameters that have been shown to predict decompensation and/or death in compensated cirrhosis. 1, 2 Six different sensitivity analyses were performed in the matched cohort: (1) in patients who did not receive HCV antiviral therapy; (2) in patients who were HCV-RNA positive; (3) excluding patients with FIB-4 less than 1.45 (patients who are less likely to have cirrhosis and may have been miscoded); (4) in statin users with more than 50% adherence; (5) excluding statin users with more than 180 days before the second fill; and (6) using an alternative definition of decompensated cirrhosis. Analyses were conducted using SAS version 9.4 (SAS Institute, Inc, Cary, NC).
Results
Of 342,157 HCV-infected patients in the CCR, 45,350 (14%) patients had cirrhosis and no human immunodeficiency virus infection. Among 40,512 patients with a visit to 1 of the included clinics, we identified 2802 statin users. After applying exclusion criteria, 1323 statin users and 12,522 nonusers were eligible for unmatched analysis (Figure 1 ). Most patients used simvastatin (85%), followed by lovastatin (10%), pravastatin (3%), rosuvastatin (1%), and fluvastatin (1%).
We were able to match 685 statin users with 2062 statin nonusers. As shown in Figure 2 , statin users had a wider range of propensity scores than nonusers and therefore we were only able to match users with propensity scores in the lower range. Only 16% of nonusers had a score greater than 0.04, compared with 87% of users. Statin users with high propensity scores (ie, those very likely to be prescribed statins) could not be matched and were excluded from matched analysis. Among the 2062 nonusers, the propensity score of the user matched to 5 decimal places for 16%, 37% were within 0.0001, 36% to 0.001, 10% to 0.02, and 1% matched to 1 decimal place. Of 685 statin users, 134 were matched to 5 nonusers, 238 were matched to 4 nonusers, 3 were matched to 212 nonusers, 87 were matched to 2 nonusers, and 14 were matched to 1 nonuser.
Baseline characteristics of unmatched and propensity score-matched users and nonusers are shown in Table 1 . The weighted average of each set of nonusers was used to represent 1 nonuser. In the unmatched cohort there were many clinically and statistically significant differences between users and nonusers, specifically, statin users were older, had a higher prevalence of smoking, coronary artery disease, hypertension, diabetes, chronic kidney disease, peripheral artery disease, and cerebrovascular disease, as well as higher cholesterol levels, LDL levels, albumin levels, and platelet count. As expected, in the propensity-matched cohort there were no differences in these parameters between statin users and nonusers, showing the validity of our model. Antiviral therapy was prescribed in 23% of the patients (20.7% of nonstatin users, 25.4% of statin users; P ¼ .04). Median adherence, as determined by the proportion of days covered, was 0.79 (interquartile range, 0.45-1.00) for cirrhosis decompensation and 0.77 (interquartile range, 0.41-1.00) for death.
Cirrhosis Decompensation
In the unmatched cohort, in a median follow-up period of 2.5 years for statin users and 1.5 years for statin nonusers, statin use was associated with a lower risk of decompensation (hazard ratio [HR], 0.22; 95% confidence interval [CI], 0.17-0.28) that remained after adjusting for age, BMI, serum albumin, FIB-4, MELD, and CTP scores ( Table 2 ).
In the matched cohort, the median follow-up period for decompensation was 2.3 years for statin users and 1.7 years for statin nonusers. There were 220 decompensation events (39 statin users and 181 nonusers). Statin use was associated with a lower risk of decompensation (HR, 0.55; 95% CI, 0.39-0.77) compared with nonuse. These findings persisted after adjustment for antiviral therapy (HR, 0.56; 95% CI, 0.39-0.79).
We further analyzed the effect of statin use on the type of decompensation. As shown in Table 3 
Death
In the unmatched cohort, statin use was associated with a lower risk of death (HR, 0.39; 95% CI, 0.34-0.44), which remained significant after adjusting for age, BMI, serum albumin, FIB-4, MELD, and CTP scores (median follow-up period of 2.6 years for statin users and 1.9 years for statin nonusers) ( Table 2 ). In the matched cohort, the median follow-up for death was 2.4 years for users and 1.9 years for nonusers. There were 667 deaths (121 users and 546 nonusers). Statin use was associated with a lower risk of death (HR, 0.56; 95% CI, 0.46-0.69) compared with nonuse. These findings persisted after adjustment for antiviral therapy (HR, 0.57; 95% CI, 0.47-0.70).
Statin use also was associated with a significantly lower risk of development of hepatocellular carcinoma (HCC) (HR, 0.42; 95% CI, 0.27-0.64) and a lower rate of liver transplantation (HR, 0.37; 95% CI, 0.15-0.96) ( Table 4 ).
Probability of Decompensation and Death
Kaplan-Meier plots for both unmatched and matched cohorts showed an advantage for statin users for both outcomes (decompensation and death) beginning approximately 1 year after the start of the follow-up period that persisted over the full 8 years of available follow-up time (Figure 3 ). Differences were attenuated in the matched cohort but remained significant (P < .001) (log-rank test and Wilcoxon test).
Sensitivity Analyses
All 6 sensitivity analyses yielded similar results to that of the main analysis in the matched cohort. Compared with nonusers, statin users had a lower risk of decompensation and death after the following: (1) excluding patients who received HCV antiviral therapy (HR, 0.59; 95% CI, 0.41-0.85 and HR, 0.56; 95% CI, 0.45-0.69, respectively); (2) NOTE. Unless otherwise indicated, results are expressed as n(%). For the unmatched cohort, statin nonusers sample were selected randomly by index date among all unique eligible nonusers. For the matched cohort, the weighted average of each group of nonusers was used to represent 1 nonuser. HDL, high-density lipoprotein; INR, international normalized ratio; IQR, interquartile range. a Prescribing patterns were developed by determining the proportion of patients in the visit pool who initiated statin use at each site by years (1997-2001, 2002-2003, and 2004-2009 ). Sites below the 25th percentile were deemed as low statin-prescribing sites, sites above the 75th percentile were deemed high statin-prescribing sites, all other sites were classified as medium. 
Discussion
In this propensity score-matched study we showed a 40% lower risk of decompensation and death with statin use in a large cohort of US veterans with compensated HCV cirrhosis. As expected, given appropriate 3 matching, multivariable analysis adjusting for predictors of death and decompensation did not alter the results. Unmatched analyses showed overly wide differences, illustrating the importance of properly accounting for confounding by indication.
Analysis of specific decompensating events in our study showed that statins were associated with a significant decrease in the development of ascites and variceal hemorrhage, the 2 main decompensating events in cirrhosis. Major determinants of decompensation in patients with compensated cirrhosis are the severity of portal hypertension (as determined by hepatic venous pressure gradient !10 mm Hg) and slight impairment in liver synthetic function (serum albumin level < 4 g/dL and MELD score > 10). 2 Simvastatin has been shown to reduce portal pressure both in experimental animals 8, 23 and in patients with cirrhosis. 9 It does this by ameliorating endotheliumdependent vasorelaxation of the liver vasculature by increasing the bioavailability of the vasodilator nitric oxide. 7 Intrahepatic vasodilatation also improves flow to the liver and may improve liver function as shown by improved clearance of indocyanine green in patients with cirrhosis. 9 Commonly used portal pressure-reducing agents such as nonselective b-blockers lack this effect because they that act by decreasing portal venous inflow, without an effect on hepatic flow. In a recent placebo-controlled study performed in patients with cirrhosis who recently had bled from varices, simvastatin improved survival without an effect on recurrent variceal hemorrhage, 24 indicating that its beneficial effect may be related mostly to liver flow amelioration and consequent improvement in liver function. Furthermore, it also has been shown that statins may decrease liver fibrosis in experimental cirrhosis and decrease the progression of fibrosis in patients with viral hepatitis. 25 Statins also have important anti-inflammatory properties in hepatocytes as well as vascular cells (endothelial, smooth muscle, immune cells). 26 Statins reduce interleukin 6-mediated C-reactive protein, 27 an acute-phase reactant, produced mostly in the hepatocytes and a marker of poor prognosis in cirrhosis. 28 Preclinical data suggest that simvastatin may attenuate liver inflammation and liver injury associated with infections or bleeding, 29 and data in human beings have shown that statins are protective in ischemic hepatitis. 30 Statin use also has been shown to suppress hepatitis C activity in vitro and in vivo, 31, 32 with recent data suggesting that the concomitant use of statins while undergoing antiviral treatment increases the likelihood of sustained virologic response. 33 Therefore, our results could be explained by various effects of statins not only in ameliorating mechanisms of portal hypertension but also potentially an antiinflammatory and antiviral effect, although the latter effect may not be as important because a simvastatin survival benefit has been described in decompensated cirrhosis of mostly an alcoholic etiology. 24 Furthermore, our results could not be explained on the basis of antiviral therapy because only a minority of patients received pegylated interferon and ribavirin, and a sensitivity analysis excluding patients receiving antiviral therapy showed the same results as in the overall group.
Our study evaluated the effect of statins in a homogeneous nationwide cohort of patients with compensated HCV cirrhosis. A previous small single-center study that combined patients with compensated and decompensated cirrhosis and that concluded that statins were not harmful, had shown that statin use was a negative predictor of death. 10 To emulate a randomized placebo-controlled trial, propensity score matching was performed and resulted in excellent balance between statin users and nonusers. This matching corrected for confounding that may have occurred because of less statin use in patients with more severe liver disease or more statin use in patients with a greater cardiovascular risk and potentially higher mortality rate. 20 As noted, only statin users with low propensity scores could be matched, thereby excluding patients with a higher probability of receiving statins. These patients likely would have been ineligible to participate in a randomized trial because they would have had a strong indication for statin use and it would have been unethical to withhold a statin. Although the cause of death cannot be obtained from this database and the decrease in mortality could be owing to a reduction in cardiovascular-related deaths, the fact that patients with a high propensity for statin use (ie, patients with a high risk of dying from a cardiovascular-related death) were excluded reduces this possibility. In addition, decompensation and HCC are important predictors of death in patients with cirrhosis, 1, 34 and because both decompensation and HCC were reduced in this cohort it seems more likely that the observed decrease in mortality was in fact owing to a reduction in decompensation and HCC. Our study confirms evidence in the literature showing a decrease in HCC with Kaplan-Meier estimates of percentages of patients dying in unmatched and propensity-matched cohorts.
statins, 35 although the mechanisms may be different from those by which statins would decrease decompensation.
We note other limitations: because ICD-9 codes were used for diagnoses, misclassification bias was a possibility and patients without cirrhosis could have been included in the study. However, cirrhosis is more likely to be underdiagnosed and even if patients without cirrhosis had been included, one would expect them to be distributed equally between study groups. All patients in this cohort had chronic HCV infection but concomitant etiologies for cirrhosis cannot be excluded because more than 50% had an ICD-9 diagnosis of alcohol dependence and the median BMI was in the overweight range. Another limitation was that the study cohort was predominantly male. This may affect the generalizability of the results but does not limit its internal validity.
Although statins can be hepatotoxic, this usually is mild and self-limited and their safety has been shown previously in patients with chronic liver disease. 36, 37 The beneficial effect of statins in our study, as it relates to decompensation and death, further supports a lack of a significant deleterious hepatotoxic effect. Statin prescriptions in patients with chronic liver disease remain low, 38 as indicated by the relatively low number of statin users in our cohort, even in patients with high cholesterol (less than half of the patients with cholesterol >200 mg/dL received a statin).
This retrospective propensity-matched cohort study performed in veterans with HCV compensated cirrhosis showed the association of statin use with a decreased risk of cirrhosis decompensation and death. Results should lead to multicenter prospective placebo-controlled randomized trials in the general nonveteran population and should stratify patients by etiology of cirrhosis. Although we cannot yet recommend statin use in all patients with compensated cirrhosis, it is important that practitioners recognize that statins should not be avoided in these patients.
